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Background: In approximately 80% of patients, ovarian cancer is diagnosed when the patient is already in the
advanced stages of the disease. CA125 is currently used as the marker for ovarian cancer; however, it lacks
specificity and sensitivity for detecting early stage disease. There is a critical unmet need for sensitive and specific
routine screening tests for early diagnosis that can reduce ovarian cancer lethality by reliably detecting the disease
at its earliest and treatable stages.
Results: In this study, we investigated the N-linked sialylated glycopeptides in serum samples from healthy and
ovarian cancer patients using Lectin-directed Tandem Labeling (LTL) and iTRAQ quantitative proteomics methods.
We identified 45 N-linked sialylated glycopeptides containing 46 glycosylation sites. Among those, ten sialylated
glycopeptides were significantly up-regulated in ovarian cancer patients’ serum samples. LC-MS/MS analysis of the
non-glycosylated peptides from the same samples, western blot data using lectin enriched glycoproteins of various
ovarian cancer type samples, and PNGase F (+/−) treatment confirmed the sialylation changes in the ovarian cancer
samples.
Conclusion: Herein, we demonstrated that several proteins are aberrantly sialylated in N-linked glycopeptides in
ovarian cancer and detection of glycopeptides with abnormal sialylation changes may have the potential to serve
as biomarkers for ovarian cancer.
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The American Cancer Society estimates that in 2011,
about 21,990 new cases of ovarian cancer will be diag-
nosed and 15,460 women will die of ovarian cancer in
the United States (ovariancancer.org) [1-3]. When ovar-
ian cancer is detected early, the five year survival rate is
over 90% [4]. Serum measurement of CA125, the
current standard, has an early stage detection rate of
only about 28% and when combined with ultrasound
still only identifies 48% [5,6]. Development of improved
diagnostic tools for early detection of ovarian cancer, in-
cluding the discovery of new ovarian cancer biomarkers,
has the potential to significantly improve the survival
rate.* Correspondence: rphilip@immunotope.com
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reproduction in any medium, provided the orIt has been shown that in the cancer transformation
process, changed expression and post translational
modification of proteins occurs, resulting in a change in
the protein structure and function. Investigating these
modifications specific for cancer may provide vital infor-
mation and serve as biomarkers for the diseased state.
Glycosylation is a common and essential form of post
translational modification of proteins. Among all the gly-
cosylation forms, sialylation has received much attention
owing to the strong correlation between the sialylation
aberration and cancer [7]. Sialic acid residues are known
to be linked via an R-2,3 or an R-2,6 bond to Gal/GalNAc
in proteins. SNA lectin binds to peptides carrying a sialic
acid residue connected to the underlying sugar chains
through an R-2,6 linkage. It has been suggested that there
is an increased branching of glycan structures in cancer
along with the increased expression both at RNA andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Shetty et al. Clinical Proteomics 2012, 9:10 Page 2 of 19
http://www.clinicalproteomicsjournal.com/content/9/1/10protein level of sialyltransferase [8-10], which leads to a
global increase in sialyation of the proteins [11]. Increased
activity of sialyltransferase is also shown to be accom-
panied by an increase in the level of enzymes, such as
ST6Gal-1, which is responsible for linking sialic acid to
galactose in colorectal, ovarian and breast cancers
[10,12-14]. ST6Gal-1 has been implicated in cell-cell
interaction, enhanced motility and increased invasive-
ness of tumor cells [10].
In the last decade, with the evolution of proteomics
and glycomics technologies, the potential for the identi-
fication of biomarkers has increased tremendously, in
spite of the extreme complexity of the serum with a dy-
namic range in concentration of several orders of magni-
tude [15]. In order to identify these low abundant
disease marker proteins in serum, various methods have
been developed to deplete the abundant proteins such as
albumin and IgG, which constitutes about 90% of the
serum protein concentration [16,17]. Alternatively, sev-
eral methods were developed to enrich a specific class of
proteins, such as glycoproteins by a lectin affinity en-
richment strategy, which can increase the chances for
the identification of elusive glycosylation changes in low
abundant proteins. Recent advances in glycoproteomics
have made it possible to probe specific glycosylation
changes [18], in particular sialylation changes [19-21], in
proteins between the disease and normal state. The level
of sialic acid was observed to be significantly elevated in
ovarian cancer patients plasma compared to the healthy
controls [19,20]. Berbec et al. [21], reported that the
average concentration of sialic acid in total serum in
ovarian cancer patients was significantly higher than in
the healthy control group and may reflect the develop-
ment of malignancy and should be considered as a sup-
porting tumor marker in ovarian cancer diagnosis. In
recent years, several groups have investigated the sialyla-
tion aberration in the glycoproteome of cancer serum
samples using diverse proteomics strategies including
lectin affinity, hydrazine chemistry, HPLC and chemical
enrichment methods [18,22-27].
In our previous work, we probed the prostate cancer
serum glycoproteome by employing the lectin-directed
tandem labeling (LTL) quantitative proteomics method
[28] and identified several N-linked sialylated glycopep-
tides that showed significant sialylation aberration be-
tween normal and prostate cancer serum samples. In the
current study, we report the results of the sialylation ab-
erration analysis in ovarian cancer-associated N-linked
glycoproteins. We employed the LTL method to identify
N-linked sialylation sites and accurately identified the
changes in sialylation between normal and ovarian can-
cer serum samples based on the N-deglycosylated pep-
tide analysis [29,30]. We used SNA lectin to capture
sialylated glycopeptides and, for quantitation, we usedacetyl (1H3/
2D3) labeling at the N-terminus in combin-
ation with 18O labeling during PNGase F digestion for
glycosylation site mapping. Further, iTRAQ quantitative
analysis of non-glycosylated peptides from the same
samples revealed that the observed sialylation changes in
cancer serum samples are independent of the glycopro-
tein concentrations. The quantitative proteomics results
were further verified by western blot analysis of SNA
enriched selected glycoproteins that are strongly impli-
cated in ovarian cancer.
Results
Identification of glycopeptides and determination of
glycosylation sites
The glycopeptide identification and glycosylation site de-
termination were achieved by following the strategy as
outlined in Figure 1. First, abundant IgG glycoproteins
were depleted from normal and ovarian cancer patients’
serum samples. Then equal amounts (5 mg each) of pro-
tein from normal and cancer serum samples were digested
by trypsin and glycopeptides containing sialic acid were
enriched by using SNA lectin. The resulting sialylated gly-
copeptides were labeled using light and heavy isotopes of
acetic anhydride reagents and mixed. Next, N-linked gly-
cans were cleaved by PNGase F in the presence of heavy
(18O) water to introduce a 3 Da mass shift with the aim
to unequivocally identify glycosylation sites. Finally, the
N-deglycosylated peptide mixture was analyzed by nano
LC-MS/MS to identify peptide sequences in addition to
determining the glycosylation sites. Each glycopeptide
identified in the database search results was inspected for
the NXS/T consensus sequence as well as for a 3 Da mass
shift. Also, the MS/MS spectrum of each glycopeptide was
verified manually and unambiguously characterized the
complete peptide sequence. For instance, two glycopep-
tides (VVLHPNYSQVDIGLIK and NLFLNHSENATAK)
were identified for haptoglobin and the tandem mass
spectrometry data in Figure 2b shows all the signature
ions (b and y ions) confirming the sequence of the light
isotope of CH3CO-VVLHPD(
18O)YSQVDIGLIK-OCCH3
glycopeptide sequence. Similarly, in the MS/MS spectrum
of Figure 2a, all b and y ions, including a shift of 3 Da
modification in b ions (b13, b14, b15) and y ions (y2, y4, y5)
due to heavy acetyl group at the N-terminus, confirm the
identity of the heavy isotope of the CD3CO-VVLHPD
(18O)YSQVDIGLIK-OCCD3 glycopeptide. It should be
noted that the above two peptides possess NXT/S consen-
sus sequences and, in both peptides, asparagine is modi-
fied to aspartic acid, as evidenced by 3 Da mass shift for
b9 ion in Figure 2a and 2b. However, the total mass is
increased by 6 Da from light labeled peptide to heavy la-
beled peptide because of the acetylation labeling at the N-
terminus as well as at the c-terminal lysine side chain. The
other haptoglobin glycopeptide, NLFLNHSENATAK, was
Figure 1 LTL quantitative proteomics strategy used for the identification and quantification of sialylated N-linked glycopeptides in
normal and ovarian cancer sera.
Figure 2 Tandem mass spectra of doubly charged ions of heavy CD3CO- VVLHPD(
18O)YSQVDIGLIK- COCD3 and CH3CO- VVLHPD(
18O)
YSQVDIGLIK- OCCH3 peptides as identified by LTL quantitative proteomics in normal and ovarian cancer sera analysis.
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glycopeptide identified with more than one glycosylation
site, as corroborated by its light and heavy labeled peptide
tandem mass spectrometry data shown in Figure 3a and
3b, respectively. Similar observations were made for
CD3CO-HAD(
18O)WTLTPLK (PON1) and CD3CO-
DIVEYYnDSD(18O)GSHVLQGR (alpha-2-glycoprotein 1,
zinc) glycopeptides as confirmed by their MS/MS data
(Figure 4). For these two proteins, the light labeled ver-
sions of the peptides were not identified in our analysis.
The total number of glycopeptides identified in the
current study and the relevant details are given in Table 1.
In total, we identified 45 glycopeptides derived from 30
sialylated glycoproteins. Overall, we were able to identify
46 glycosylation sites in 45 N-linked glycopeptides and all
these sites have been reported in the literature (Swissprot
database). The majority of the sialylated glycopeptides
identified in the current study were previously reported by
various proteomics methods signifying the strength of our
LTL quantitative method to investigate glycosylation aber-
rations and glycosylation sites in proteins in cancer. Fur-
thermore, identification of low abundant serum proteins
including PON 1 (25 μg/mL) [31], Ficolin-3 (32.4 μg/mL)
[32], and Kallikrein (2.9 μg/mL) [33] in our analysis dem-
onstrate the high sensitivity of the LTL method.
Quantitative analysis
We investigated the differences in sialylated glycopep-
tides in normal and ovarian cancer serum samples byFigure 3 Tandem mass spectra of doubly charged ions of heavy CD3C
(18O)HSED(18O)ATAK- OCCH3 peptides as identified by LTL quantitativquantitating the N-deglycosylated peptides as described
in the experimental procedure. Table 1 summarizes the
results of the quantification of N-deglycosylated peptides
and the corresponding proteins. As evident in Table 1,
quantitative ratios are very different and vary signifi-
cantly between different peptide sequences of each pro-
tein suggesting prominent differences at the site of
sialylation. For example, the sialylation of glycopeptides
VVLHPNYSQVDIGLIK (haptoglobin), NLFLNHSENA-
TAK (haptoglobin), HANWTLTPLK (PON1) and
DIVEYYNDSNGSHVLQGR (alpha-2-glycoprotein 1,
zinc) are increased by 2.7 fold, 2.0 fold, 4 fold and 2 fold,
respectively, as confirmed by the XIC’s of their light and
heavy isotopes (Figure 5). Similarly, out of 30 glycopro-
teins, sialylation is increased in 10 proteins that are iden-
tified by multiple N-deglycosylated peptides in ovarian
cancer serum samples. However, sialylation is not
increased in all the glycopeptides from these up-
regulated glycoproteins and. interestingly; we were also
able to identify differential sialylation in multiple glyco-
peptides from a single protein. For example, three N
linked glycopeptides (EHEGAIYPDNTTDFQR – 3 fold
increase, ENLTAPGSDSAVFFEQGTTR- 1.9 fold in-
crease, AGLQAFFQVQECNK – and 2.2 fold decrease)
were identified in ceruloplasmin protein with differential
sialylation (Table 1). In contrast, we identified only one
glycopeptide, NTTCQDLQIEVTVK with a 3 fold de-
crease in sialylation and no change was observed in the
other glycopeptide, GLNVTLSSTGR, from ComplementO- NLFL D(18O)HSED(18O)ATAK- COCD3 and light CH3CO- NLFL D
e proteomics in normal and ovarian cancer sera analysis.
Figure 4 Tandem mass spectrum of doubly charged ions of (a) heavy CD3CO- HA D(
18O)WTLTPLK peptide and (b) CD3CO-DIVEYYNDSD
(18O)GSHVLQGR. Peptide as identified by LTL quantitative proteomics in normal and ovarian cancer sera analysis.
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tion was increased in 10 peptides and decreased in 2
peptides by more than 2 fold in each case. Standard de-
viation in the current ovarian cancer glycopeptide ana-
lysis was assumed to be 9% based on our previous
triplicate analysis of Fetuin N-linked glycopeptides using
the LTL quantitative proteomics method [28].
In order to determine whether the changes in sialy-
lated glycopeptides are a result of the alterations in the
level of sialic acid at the identified site or at the concen-
tration of the parent glycoprotein levels, we performed
quantitative analysis of the non-glycosylated peptides
obtained from the same samples. These peptides were
obtained from the flow- through peptide mixtures of the
SNA lectin enrichment step of normal and cancer serum
samples. The non-glycosylated peptides were further
purified, labeled by iTRAQ reagents (in triplicate), frac-
tionated by SCX chromatography and analyzed by LC-
MS/MS experiments (in triplicate) using Orbitrap MS.
Quantitative analysis was performed using proteome dis-
coverer software. We identified more than 100 serum
proteins out of which 28 glycoproteins were identified in
the N-deglycosylated peptide analysis using the LTL
method (Table 2). The concentration remainedunchanged for all the 28 proteins between normal and
ovarian cancer serum samples with overall heavy to light
ratios ranged from 0.8 to 1.5. These 28 proteins also in-
clude the 9 glycoproteins identified by LTL method in
which the sialylation, as analyzed by the glycopeptides, is
increased (indicated with asterisk in Table 1). This sug-
gests that sialylation indeed increased in ovarian cancer
for the 10 N-linked glycopeptides corresponding to the
9 glycoproteins identified by the LTL method and it is
independent of their protein concentration. For the
remaining 18 proteins, we observed no change in sialyla-
tion or protein concentration levels.
Western blot analysis
Validation of differentially sialylated glycoproteins
To further verify our quantitative results obtained by LTL
and iTRAQ methods, western blot analysis was performed
using specific antibodies targeting the selected serum gly-
coproteins. We selected haptoglobin and PON1 [34],
based on the implication of their glycosylation, in particu-
lar the sialylation aberration in ovarian cancer and other
cancers. Zinc-alpha-2-glycoprotein was chosen due to its
significant biomarker potential for various cancer indica-
tions [35]. Western blot analysis was performed using
Table 1 List of identified glycosylation sites and the results of quantitation of N-deglycosylated peptides
Swissprot
ID


















Proteins with increase in sialylation
P01009 Alpha-1-antitrypsin† 2.1
YLGNATAIFFLPDEGK* 271 2 902.29 1802.57 1802.90 -0.33 88 2.1
O75882 Attractin† 2.2
NHSCSEGQISIFR* 731 2 791.71 1581.41 1581.71 -0.31 54 2.2
P00738 Haptoglobin† 2.4
VVLHPNYSQVDIGLIK* 241 2 941.60 1881.18 1881.01 0.17 51 2.7
NLFLNHSENATAK 207,211 2 775.05 1548.08 1547.72 0.36 68 2.0
P02787 Serotransferrin† 5.4
CGLVPVLAENYNK* 432 2 763.12 1524.23 1523.76 0.47 88 7.6




HANWTLTPLK* 253 2 614.82 1227.63 1227.65 -0.03 58 4.0
P04114 Apolipoprotein B-100† 1.5
FVEGSHNSTVSLTTK* 3411 2 827.75 1653.48 1653.81 -0.33 91 2.0
YDFNSSMLYSTAK 3465 2 795.71 1589.41 1589.68 -0.27 68 1.0
P02790 Hemopexin† 1.9
ALPQPQNVTSLLGCTH* 453 2 897.77 1793.52 1793.88 -0.36 83 2.1
SWPAVGNCSSALR 187 2 725.38 1448.75 1448.66 0.09 83 1.6
P25311 Zinc-alpha-2-glycoprotein† 1.5
FGCEIENNR 128 2 592.57 1183.14 1182.48 0.65 71 0.9
DIVEYYNDSNGSHVLQGR* 109 2 1057.82 2113.63 2112.96 0.67 54 2.0
Proteins with increase and decrease in sialylation
P00450 Ceruloplasmin† 1.8
EHEGAIYPDNTTDFQR* 138 2 971.00 1939.99 1939.85 0.14 91 3.1
AGLQAFFQVQECNK 358 2 864.07 1726.13 1725.79 0.35 99 0.4
















Table 1 List of identified glycosylation sites and the results of quantitation of N-deglycosylated peptides (Continued)
Proteins with no change in sialylation
P02763 Alpha-1-acid glycoprotein 1 1.8
QDQCIYNTTYLNVQR 93 2 982.56 1963.11 1962.90 0.20 78 1.8
P19652 Alpha-1-acid glycoprotein 2 1.0
QNQCFYNSSYLNVQR 93 2 985.07 1968.12 1967.87 0.25 79 1.0
P01011 Alpha-1-antichymotrypsin 1.3
YTGNASALFILPDQDK 271 2 927.47 1852.93 1852.89 0.04 73 1.3
P02765 Alpha-2-HS-glycoprotein 1.4
VCQDCPLLAPLNDTR 156 1 1816.60 1815.59 1815.83 -0.24 56 1.3
KVCQDCPLLAPLNDTR 156 2 997.06 1992.10 1991.98 0.12 68 1.1
AALAAFNAQNNGSNFQLEEISR 176 2 1207.45 2412.88 2412.16 0.72 107 1.6
P01008 Antithrombin-III 1.8
SLTFNETYQDISELVYGAK 187 2 1136.45 2270.88 2270.10 0.78 53 1.8
P10909 Clusterin 1.1
LANLTQGEDQYYLR 374 2 864.74 1727.47 1727.82 -0.35 80 1.1
P00748 Coagulation factor XII 1.4
NHSCEPCQTLAVR 433 2 808.78 1615.55 1615.69 -0.14 69 1.4
P02749 Beta-2-glycoprotein 1 0.8
VYKPSAGNNSLYR 162 2 778.62 1555.22 1554.75 0.47 45 1.1
LGNWSAMPSCK 253 2 680.39 1358.77 1358.60 0.17 56 1.4
P08603 Complement factor H 1.4
MDGASNVTCINSR 1029 2 745.00 1487.99 1487.63 0.36 49 1.0
IPCSQPPQIEHGTINSSR 882 2 1033.76 2065.51 2064.97 0.54 90 1.9
P36980 Complement factor H-related
protein 2
1.8




AQLLQGLGFNLTER 96 2 804.87 1607.73 1606.86 0.87 74 1.6
O75636 Ficolin-3 1.1
















Table 1 List of identified glycosylation sites and the results of quantitation of N-deglycosylated peptides (Continued)
Q08380 Galectin-3-binding protein 1.5
ALGFENATQALGR 69 2 696.82 1391.63 1391.69 -0.06 66 1.5
P05546 Heparin cofactor 2 1.7




GAFISNFSMTVDGK 118 2 781.10 1560.18 1559.70 0.48 93 1.0
P03952 Kallikrein 1.2
IYSGILNLSDITK 453 2 762.29 1522.57 1522.80 -0.23 90 1.2
P01042 Kininogen-1 1.2
LNAENNATFYFK 294 2 740.53 1479.05 1478.70 0.35 80 1.2
ITYSIVQTNCSK 205 2 731.20 1460.38 1460.71 -0.33 64 1.6
YNSQNQSNNQFVLYR 48 2 967.71 1933.40 1932.88 0.52 0.52 0.9
P05155 Plasma protease C1 inhibitor 1.3
DTFVNASR 238 2 479.10 956.18 956.45 -0.27 38 1.3
P00734 Prothrombin 1.8
NFTENDLLVR 416 2 634.62 1267.22 1267.63 -0.41 45 1.8
P04004 Vitronectin 1.2
NGSLFAFR 169 2 485.67 969.32 969.48 -0.16 53 1.2
Proteins with dicrease in sialylation
P0C0L4 Complement C4-A 0.7
GLNVTLSSTGR 1335 2 575.20 1148.39 1148.59 -0.20 72 1.2
NTTCQDLQIEVTVK 1391 2 875.54 1749.07 1748.83 0.24 72 0.3
List of identified glycosylation sites and the results of quantitation of N-deglycosylated peptides obtained from normal and ovarian cancer sera by using LTL quantitative proteomics method.
* The RSD of this method is 9% as determined by the reproducibility studies with fetuin [28].
















Figure 5 The XIC’s and quantitative ratios of light and heavy deglycosylated peptides identified in the LTL proteomics analysis of
ovarian cancer serum. These ratios were obtained by calculating the peak areas in the XIC’s of precursor peptides using Xcalibur software.
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of normal and cancer serum samples (Figure 6). The data
indicates that before SNA enrichment, there is no signifi-
cant difference in the levels of haptoglobin and zinc-
alpha-2-glycoprotein between the normal and cancer
serum samples, whereas cancer serum contained lower
levels of the PON1 glycoprotein. The western data is in
agreement with the non-glycosylated peptide analysis,
which showed no difference between normal and cancer
samples at the protein level. However, after SNA lec-
tin enrichment, haptoglobin, PON1 and zinc-alpha-2-
glycoproteins show a significant increase in protein
concentration and their levels are comparable to the
deglycosylated peptide H/L ratios (Figure 6a) indicating
that the sialylation is indeed increased in these proteins
in ovarian cancer. Overall, the western blot data corro-
borates the LTL quantitative ratios of the deglycosylated
peptides. The minor differences between the western
blot data and the glycopeptide quantitation results may
be attributed to the contribution of the O-linked sialy-
lated fraction of each protein which is further investi-
gated as described below.Individual patient sample analysis
In order to ascertain the effect of pooling of the patient
samples on the sialylation differences between normal
and cancer, we have performed western blot analysis of
individual samples obtained from serous, endometroid
and clear cell carcinoma of stage I and Stage II-IV ovarian
cancer patients. These samples were subjected to SNA
lectin enrichment and probed with PON1 and haptoglo-
bin antibodies. We also ran the pooled stage I and stage
II-IV samples and pooled healthy female samples as con-
trols and the corresponding data is given in Figure 6b. We
observed no significant differences between the stages and
types of ovarian cancers. In general, there was only a small
difference between the cancer samples and the healthy
controls at the glycoprotein level as assessed by the
western blot.
Investigation of O-sialylated glycoprotein contribution
We have also carried out PNGase (+/−) experiments after
SNA enrichment of intact glycoproteins and western blot
analysis using haptoglobin specific antibodies. As illu-
strated in Figure 6c, multiple bands were identified in the
Table 2 List of glycoproteins identified and their iTRAQ quantitative ratios obtained from the triplicate analysis of









P01011 Alpha-1-antichymotrypsin 6 13.2 1.5±0.03
P01008 Antithrombin-III 7 14.4 1.5±0.07
P02763 Alpha-1-acid glycoprotein 1 4 17.4 1.3±0.14
P04114 Apolipoprotein B-100 63 12.8 1.3±0.09
P00748 Coagulation factor XII 3 4.1 1.3±0.39
P19652 Alpha-1-acid glycoprotein 2 3 12.9 1.3±0.17
P01009 Alpha-1-antitrypsin 12 26.3 1.2±0.23
P00738 Haptoglobin 12 26.4 1.2±0.02
P00450 Ceruloplasmin 11 10.6 1.2±0.02
P25311 Zinc-alpha-2-glycoprotein 5 17.1 1.1±0.02
P05155 Plasma protease C1 inhibitor 3 5.6 1.1±0.03
P36980 Complement factor H-related protein 2 3 11.1 1±0.20
P02790 Hemopexin 7 15.2 1±0.04
P0C0L4 Complement C4-A 26 14.3 1±0.05
P00734 Prothrombin 8 14.8 1±0.04
P08185 Corticosteroid-binding globulin 2 4.0 1±0.10
P02749 Beta-2-glycoprotein 1 2 7.5 0.9±0.08
P27169 Serum paraoxonase/arylesterase 1 5 13.0 0.9±0.05
O75882 Attractin 6 4.3 0.9±0.07
P08603 Complement factor H 17 15.0 0.9±0.11
P10909 Clusterin 6 11.6 0.9±0.03
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 10 9.5 0.8±0.09
P03952 Plasma kallikrein 8 11.9 0.8±0.13
P04004 Vitronectin 4 7.3 0.8±0.03
P05546 Heparin cofactor 2 7 13.2 0.8±0.04
P01042 Kininogen-1 11 16.0 0.8±0.06
P02765 Alpha-2-HS-glycoprotein 7 19.4 0.8±0.03
P02787 Serotransferrin 26 41.4 0.7±0.06
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(SI and SII-IV) samples. The identification of multiple
bands may be explained due to the glycosylation hetero-
geneity in haptoglobin and partial cleavage of N-linked
glycans by PNGase treatment. However, only a very low
intense band was identified at the 50 kDa region in
PNGase (+) experiment as compared to the PNGase (−)
experiment. This observation is true for both the normal
and cancer (SI and SII-IV) samples, although the inten-
sity of the 50 kDa band in PNGase (+) experiment is
slightly higher in case of the cancer sample. This suggests
that the amount of O-linked sialylated haptoglobin con-
tributing to the N-linked sialylated haptoglobin in SNA
enrichment process is very low and it may not have a
major impact in the determination of sialylation differ-
ences at the glycopeptides level between normal andcancer. Thus we have proved that the sialylation differ-
ences in N-linked glycopeptides of haptoglobin are in-
deed true and significant.
Discussion
The strategy involving the investigation of glycan specific
changes at the glycopeptide level has many advantages
and it is indeed important over examining the same
changes at the protein level. It is very well established
that the glycosylation changes are unique to a particular
site in a glycoprotein and its association with various
cancers. It is not possible to accurately examine these
changes at the glycoprotein level due to the high glyco-
protein heterogeneity and technical limitations. Enrich-
ment of intact glycoproteins using lectins may be
comprised by a mixture of N-linked and O-linked
Figure 6 Western blot analysis: a) Validation of differentially sialylated glycoproteins b) Investigation of O-sialylated glycoprotein
contribution c) Pooling vs individual patient sample analysis.
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guity in the assessment of their actual concentrations by
validation experiments like western blot. Therefore,
prior investigation of the dynamic glycosylation changes
at the glycopeptide level is imperative to discover poten-
tial cancer specific biomarkers.
Lectin enrichment has been widely used to augment
glycoprotein biomarker discovery in various cancers
[7,27,28]. In order to investigate sialic acid aberrations,
SNA lectin was used to enrich sialic acid containing glyco-
proteins in ovarian cancer. Glycosylation differences in N-
linked glycopeptides was analysed by finding differences
indirectly in deglycosylated peptides without compromis-
ing the glycan selection. Recently Ueda et al. [27], devel-
oped a novel isotopic glycosidase elution and labeling on
lectin-column chromatography (IGEL) method, which is
equally useful to investigate glycosylation changes at the
peptide level and up to 8 samples can be analyzed simul-
taneously using iTRAQ technology. Herein, we used the
LTL method to investigate the global sialylation changes
in ovarian cancer on each glycoprotein via deglycosylated
peptide analysis. There are many advantages associated
with the LTL method [28] in probing the glycosylation
changes at the glycopeptide level. In this study, we
observed the consensus NXS/T sequence and an 18O tag
in each glycopeptide identified, which significantly in-
creased the confidence and enabled the identification of
true positive N-glycopeptides based on the 3Da mass shift
at the glycosylation site. This approach not only simplified
the complexity of various glycopeptides, but also increased
the sensitivity considerably to identify a particularsialylated peptide with high quantitative accuracy on the
sialylation changes.
Quantitative analysis of deglycosylated and non-
glycosylated peptides revealed a significant increase in
sialylation of the glycoproteins while the concentration
of the glycoproteins remained unchanged in ovarian
cancer (Table 1). Western blot analysis of SNA enriched
selected glycoproteins further confirmed this observation
(Figure 6). Our results are further supported by reports
in the literature on the implication of the selected pro-
teins in various cancers including ovarian cancer. Up-
regulation of glycosylation in haptoglobin has been
reported in pancreatic cancer [36-38]. Glycopeptide,
NLFLNHSENATAK from haptoglobin has been reported
to have de-sialylated, mono-sialylated and completely
sialylated glycan structures, while, only the completely
sialylated structure has been shown to be up-regulated
in pancreatic cancer samples compared to the controls
[7]. In addition to the changes in glycosylation, elevation
of the haptoglobin protein levels in the serum and ascitic
fluid of ovarian cancer patients has been reported in pre-
vious studies [38,39]. Similarly, PON1 has been impli-
cated in ovarian cancer and it was shown to be involved
in a variety of enzymatic activities including lactonase,
arylesterase, peroxidase, and phospholipase activities
[34]. It has been suggested that women who carry PON1
alleles associated with reduced PON1 activity and those
with lower concentrations might be at higher risk for
developing ovarian cancer [40]. It was also reported that
PON1 genetic variants may alter the risk of epithelial
ovarian cancer among smokers and obese women. Zinc-
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biomarkers for predicting the response to thalidomide-
based therapy in newly diagnosed multiple myeloma
patients [41]. It is also a potential molecular marker for
biochemical relapse in men with margin-positive, loca-
lized prostate cancer [42], and differential regulation of
this protein has been linked to gastrointestinal cancer
[43], prostate cancer [44], cancer cachexia [45], and
bladder cancer [46]. However, no glycosylation aberra-
tion was reported for this protein and linked to any can-
cer including ovarian cancer. On the contrary, we found
significant increase in sialylation in our deglycosylated
peptide and western blot analysis of SNA enriched ovar-
ian cancer serum samples. Our data suggests that glyco-
sylation aberrations, as assessed at the glycopeptides
level, are a highly sensitive and specific tool for bio-
marker discovery in various cancers.
Significant sialylation aberrations were observed in
ovarian cancer when we compared our quantitative
results on the sialylated glycopeptides corresponding to
the glycoproteins reported in the literature. Similar to
our findings, changes in glycosylation have been
reported for alpha-1-antitrypsin glycoprotein in ovarian
cancer patients [47]. Glycosylation changes in serotrans-
ferrin have not been reported earlier in ovarian cancer.
However, ovarian cancer cells have been shown to se-
crete serotransferrin in chemically defined medium and
up-regulation of serum levels of four isoforms of sero-
transferrin have been observed in 42% of cancer patients
after six cycles of chemotherapy [48]. In Our study in
which significant changes in serotransferrin sialylation
were observed in multiple glycopeptides in ovarian can-
cer (Table 1), along with published reports suggesting
serotransferrin could be a potential biomarker for ovar-
ian cancer at both glycoprotein and glycopeptides level.
Furthermore, Liu et al. [49], reported significant sialyla-
tion changes in TLNQSSDELQLLSMGNAMFVK glyco-
peptide and no change in the LSLGAHNTTLTEILK
glycopeptide, from alpha-1-antichymotryspin glycopro-
tein in ovarian cancer. In our analysis, we identified a
different sialylated peptide, YTGNASALFILPDQDK
from alpha-1-antichymotryspin with no change in
silaylation.
Evaluation of individual vs pooled samples of various
types and stages of ovarian cancer by western blot analysis
revealed no differences at the glycoprotein level suggesting
there is minimal loss of significance in using pooled sam-
ples for discovery of biomarkers. However, extensive vali-
dations have to be performed with significant number of
individual samples prior to the selection of potential bio-
markers for diagnostics development. In general, our data
is in accordance with previously reported studies and
emphasizes that the sialylation status of the glycopro-
teome in cancer is highly dependent on the type ofsamples compared and disease status and is independent
of the concentration of the parent glycoproteins.
We recently reported the sialylation aberrations in
prostate cancer serum samples by employing the LTL
method and unambiguously identified and quantitated
45 N-linked sialylated glycopeptides. In this study, we
compared the N-linked sialylated glycopeptidome of
prostate cancer serum samples with ovarian cancer data.
The results of the comparative analysis of all the glyco-
peptides identified in these two cancers are given in
Table 3. Interestingly, a majority of the glycopeptides
identified in prostate cancer was also identified in ovar-
ian cancer; however, we observed significant differences
in the sialylation of most of these glycopeptides in these
two cancers. While the sialylation of 6 glycopeptides
increased in both cancers, the sialylation of 5 other gly-
copeptides increased only in ovarian cancer. In addition,
the sialylation is significantly elevated in 16 glycopep-
tides only in prostate cancer suggesting the differential
prevalence of sialylation aberration in various cancers.
Although 28 glycopeptides were common to these two
cancers, 17 glycopeptides were uniquely identified in
ovarian cancer and 17 different glycopeptides were
uniquely identified in prostate cancer (Figure 7). The
data is intriguing as to the potential of glycosylation
aberrations at the glycopeptide level as cancer specific
biomarkers.
Conclusions
We successfully used LTL and iTRAQ quantitative pro-
teomics methods in conjunction with western blot ana-
lysis to investigate the sialylation aberration in N-linked
glycopeptides in normal and ovarian cancer serum sam-
ples. In the current study, we identified 30 glycoproteins
with 45 N-linked sialylated glycopeptides comprising 46
glycosylation sites. We observed increases in sialyation
of 10 N-linked glycopeptides in ovarian cancer, which is
independent of their protein concentrations as con-
firmed by the non-glycosylated peptide analysis. Sialyla-
tion change in some of the selected peptides was also
confirmed by the western blot analysis of SNA enriched
precursor glycoproteins. Overall, we observed a good
correlation between the proteomic analysis and western
blot experiments. These integrated results strongly suggest
that haptoglobin, PON1 and zinc-alpha-2-glycoprotein
may undergo specific sialylation changes at the glycoep-
tide level in ovarian cancer.
Further, the comparative analysis of N-linked sialylated
glycopeptides from ovarian and prostate cancer serum
samples revealed major variation in the level of sialyla-
tion in these two cancers. The increased cancer specific
sialylation in the N-glycopeptides in these two cancers
also implies that the glycopeptides are potential targets
for biomarker discovery. These preliminary observations




Protein Glycopeptide sequence Heavy/Light ratio (peptide)
Ovarian cancer Prostate cancer
increase of sialylation in ovarian cancer and prostate cancer
P00738 Haptoglobin NLFLNHSENATAK 2.0 3.1
VVLHPNYSQVDIGLIK 2.7 3.8
P00450 Ceruloplasmin EHEGAIYPDNTTDFQR 3.1 3.9
P02790 Hemopexin ALPQPQNVTSLLGCTH 2.1 3.8
P04114 Apolipoprotein B-100 FVEGSHNSTVSLTTK 2.0 2.9
P01009 Isoform 1 of Alpha-1-antitrypsin YLGNATAIFFLPDEGK 2.1 5.5
increase of sialylation only in ovarian cancer
P27169 Serum paraoxonase/arylesterase 1 HANWTLTPLK 4.0 ▬
P02787 Serotransferrin CGLVPVLAENYNK 7.6 1.1
QQQHLFGSNVTDCSGNFCLFR 3.1 ▬
O75882 Attractin NHSCSEGQISIFR 2.2 ▬
P25311 Zinc-alpha-2-glycoprotein DIVEYYNDSNGSHVLQGR 2.0 ▬
increase of sialylation only in prostate cancer
P36980 Complement factor H-related protein 1 LQNNENNISCVER 1.8 2.2
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 GAFISNFSMTVDGK 1.0 4.2
P08603 Isoform 1 of Complement factor H IPCSQPPQIEHGTINSSR 1.9 3.5
ISEENETTCYMGK ▬ 2.8
MDGASNVTCINSR 1.0 2.3
P04004 Vitronectin NNATVHEQVGGPSLTSDLQAQSK ▬ 2.4
P02765 Alpha-2-HS-glycoprotein AALAAFNAQNNGSNFQLEEISR 1.6 3.7
KVCQDCPLLAPLNDTR 1.1 4.3
VCQDCPLLAPLNDTR 1.3 2.4
P02763 Alpha-1-acid glycoprotein 1 QDQCIYNTTYLNVQR 1.8 2.1
P00450 Ceruloplasmin ENLTAPGSDSAVFFEQGTTR 1.9 3.1
AGLQAFFQVQECNK 0.4 6.8
P02790 Hemopexin SWPAVGNCSSALR 1.6 4.4
P27169 Serum paraoxonase/arylesterase 1 VTQVYAENGTVLQGSTVASVYK ▬ 2.1
P01042 Isoform HMW of Kininogen-1 ITYSIVQTNCSK 1.6 2.5
LNAENNATFYFK 1.2 5.0
P01871 IGHM protein GLTFQQNASSMCVPDQDTAIR ▬ 4.7
YKNNSDISSTR ▬ 2.3
increase of sialylation in ovarian cancer and prostate cancer
P00738 Haptoglobin NLFLNHSENATAK 2.0 3.1
VVLHPNYSQVDIGLIK 2.7 3.8
P00450 Ceruloplasmin EHEGAIYPDNTTDFQR 3.1 3.9
P02790 Hemopexin ALPQPQNVTSLLGCTH 2.1 3.8
P04114 Apolipoprotein B-100 FVEGSHNSTVSLTTK 2.0 2.9
P01009 Isoform 1 of Alpha-1-antitrypsin YLGNATAIFFLPDEGK 2.1 5.5
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Table 3 List of differentially sialylated glycopeptides identified and quantitated in ovarian cancer and prostate cancer
sera (Continued)
increase of sialylation only in ovarian cancer
P27169 Serum paraoxonase/arylesterase 1 HANWTLTPLK 4.0 ▬
P02787 Serotransferrin CGLVPVLAENYNK 7.6 1.1
QQQHLFGSNVTDCSGNFCLFR 3.1 ▬
O75882 Attractin NHSCSEGQISIFR 2.2 ▬
P25311 Zinc-alpha-2-glycoprotein DIVEYYNDSNGSHVLQGR 2.0 ▬
increase of sialylation only in prostate cancer
P36980 Complement factor H-related protein 1 LQNNENNISCVER 1.8 2.2
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 GAFISNFSMTVDGK 1.0 4.2
P08603 Isoform 1 of Complement factor H IPCSQPPQIEHGTINSSR 1.9 3.5
ISEENETTCYMGK ▬ 2.8
MDGASNVTCINSR 1.0 2.3
P04004 Vitronectin NNATVHEQVGGPSLTSDLQAQSK ▬ 2.4
P02765 Alpha-2-HS-glycoprotein AALAAFNAQNNGSNFQLEEISR 1.6 3.7
KVCQDCPLLAPLNDTR 1.1 4.3
VCQDCPLLAPLNDTR 1.3 2.4
P02763 Alpha-1-acid glycoprotein 1 QDQCIYNTTYLNVQR 1.8 2.1
P00450 Ceruloplasmin ENLTAPGSDSAVFFEQGTTR 1.9 3.1
AGLQAFFQVQECNK 0.4 6.8
P02790 Hemopexin SWPAVGNCSSALR 1.6 4.4
P27169 Serum paraoxonase/arylesterase 1 VTQVYAENGTVLQGSTVASVYK ▬ 2.1
P01042 Isoform HMW of Kininogen-1 ITYSIVQTNCSK 1.6 2.5
LNAENNATFYFK 1.2 5.0
P01871 IGHM protein GLTFQQNASSMCVPDQDTAIR ▬ 4.7
YKNNSDISSTR ▬ 2.3
List of differentially sialylated glycopeptides identified and quantitated in ovarian cancer and prostate cancer sera by using LTL quantitative proteomics method.
Figure 7 Venn diagram showing the overlap and unique
desialylated peptides identified in ovarian cancer sera and
prostate cancer sera.
Shetty et al. Clinical Proteomics 2012, 9:10 Page 14 of 19
http://www.clinicalproteomicsjournal.com/content/9/1/10were further confirmed by screening individual samples
of various types and stages of ovarian cancer by western
blot analysis, and the current data clearly demonstrate
that the sialylation changes are unique to each N-linked
glycopeptide glycosylation in a particular type of cancer
and this approach may have a high potential for the de-
velopment of early diagnostic strategies for cancer in
general.Methods
Serum samples
Serum samples were procured from ten patients with
histologically confirmed ovarian carcinoma (primary
diagnosis, regardless of stage of the disease), prior to
surgery and chemotherapy. Patient samples were
obtained under IRB approved protocols from patients
undergoing treatment at Duke University Medical Cen-
ter. Equal number (4 each) of serous adenocarcinoma,
endometroid adenocarcinoma and clear cell carcinoma
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five age matched healthy female control individuals were
purchased from Research Blood Components, LLC
(Brighton, MA). Equal amounts of undiluted serum from
each cohort were used to generate composites consisting
of cancer and normal serum samples for the study.Chemicals and reagents
HPLC grade acetonitrile (ACN) and water were obtained
from Burdick and Jackson (Muskegon, MI). Methanol, cal-
cium chloride (CaCl2) and sodium phosphate (NaH2PO4)
were purchased from EMD chemical Inc. (Gibbstown,
NJ). Ethanol was purchased from Decon Labs, Inc. (King
of Prussia, PA). Acetic anhydride (1H6/
2D6), H2
18O water,
phenylmethanesulfonyl fluoride (PMSF), ammonium bi-
carbonate (AB), formic acid (FA), trifluoroacetic acid
(TFA), dithiothreitol (DTT), iodoacetamide (IA), manga-
nese chloride (MnCl2), lactose were purchased from
Sigma (St. Louis, MO). Sambucus nigra lectin (SNA) agar-
ose was purchased from Vector Laboratories (Burlingame,
CA). Spin-x columns were purchased from Corning, Inc.
(Lowell, MA). Peptide-N-glycosidase F (PNGase F) was
purchased from QA BIO (Palm Desert, CA). Protein A/G
beads and C-18 miniprep columns were purchased from
Thermo Scientific (Waltham, MA). RapiGest SF, vacuum
manifold and C-18 sep-pak cartridges were obtained from
Waters (Milford, MA). Tris, NaCl and NaOH were pur-
chased from Fisher (Pittsburgh, PA). PBS was purchased
from Mediatech, Inc. (Manassas, VA). Ultra Centricon 3
kDa filters were purchased from Millipore (Billerica, MA).
Trypsin was purchased from Promega (Madison, WI).
iTRAQ labeling kit was purchased from Applied Biosys-
tems (Bedford, MA).In-solution digestion
Prior to the in-solution digestion, serum samples were
pre-cleared with spin-x columns and IgG was removed
using protein A/G beads and buffer exchanged with 50
mM AB using Ultra Centricon 3 kDa filters. The protein
concentrations of normal and cancer serum samples
were calculated by nanodrop technologies instrument
(Wilmington, DE).
Briefly, the protein solution was mixed with 50 μl of
50 mM AB containing 0.1% of Rapigest SF and the pro-
tein was reduced with DTT (5 μm/μl in 50 mM AB) by
incubating the mixture at 65°C for 45 min and alkylated
with IA (15 μm in 50 mM AB) by incubating the reac-
tion mixture in dark for 30 min. Then the alkylated gly-
coproteins were digested by trypsin (5 ng/μl in 50 mM
AB) overnight at 37°C in a water bath. RapiGest was
removed according to the vendor’s recommended
protocol.Enrichment of glycopeptides using SNA lectin
Tryptic peptides were mixed with 1 mM solution of
PMSF prior to the glycoprotein enrichment by SNA lec-
tin. The tryptic peptide sample was diluted to 4:1 with 5
× binding buffer (100 mM Tris, 750 mM NaCl, 5 mM
CaCl2 and 5 mM MnCl2, pH 6.7). The lectin columns
were prepared by adding 200μl of SNA lectin to the car-
tridges and spun down at 1000 × g for 1 min to remove
storage buffer. The lectin resin in columns was washed
with 200 μl (2 ×) of 1 × washing buffer (20 mM Tris,
150 mM NaCl, 1mM CalCl2 and 1 mM MnCl2). Then
the sample was loaded onto the columns, mixed and
incubated at room temperature (RT) for 10 min. The
columns were centrifuged to collect the flow through
and washed with 400 μl of 1 × washing buffer (2 ×).
Again, 400 μl of 1 × washing buffer was added and incu-
bated for 5 min at RT (2 ×). The flow through from
samples was saved for additional labeling experiments.
Finally, the glycopeptides were eluted from the lectin
columns by adding 200 μl (2 ×) of elution buffer (20
mM Tris, 150 mM NaCl, 1mM CalCl2, 1 mM MnCl2
and 200 mM lactose) and incubating for 10 min at RT.
The flow through containing the glycopeptides were
collected by centrifugation and purified by C-18
chromatography.Acetylation of glycopeptides
Glycopeptides obtained from normal and ovarian cancer
serum samples and non-glycosylated serum peptides
(lectin column flow through) were labeled with acetyl
(1H3/
2D3) groups according to a published protocol [50].
Briefly, 2 μl of 1H6-acetic anhydride or
2D6-acetic anhyd-
ride [50% (vol/vol) in methanol] were added to 100 μl of
peptide mixture in 50% methanol/water (vol/vol). The
mixture was allowed to react at 22°C for 15 min. The re-
action was stopped by the addition of 2.2 μl of formic
acid and equal aliquots of both samples were mixed.PNGase F digestion of glycopeptides
The light (normal) and heavy (cancer) N-terminus/lysine
labeled serum glycopeptides were mixed and digested
with PNGase F to cleave the N-glycans from peptides
according to the protocol described elsewhere [51].
Briefly, the glycopeptides were dried in vacuum and re-
dissolved in 100 mM NaH2PO4 buffer (pH 7.5). The
PNGase F enzyme was dissolved in 50 mM AB.
NaH2PO4 buffer solution and AB buffer solution were
prepared in H2
18O before dissolving glycopeptides and
enzyme, respectively. The reaction mixture was incu-
bated with 6 μl of PNGase F at 37°C overnight. The re-
action was stopped by adding 0.5% TFA solution. The
resulting N-deglycosylated peptides were purified by C-
18 chromatography.
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The trypsin digested peptides, SNA enriched glycopep-
tides and N-deglycosylated peptides were purified by C-
18 reversed-phase (RP) chromatography using C-18 spin
columns with the help of a vacuum manifold. Briefly, the
C-18 columns were activated with 50% acetonitrile and
equilibrated with a buffer containing 2% ACN and 0.1%
TFA in water. Then peptide mixture (dissolved in 2%
ACN and 0.1% TFA in water) was slowly loaded into the
C-18 cartridge. Then the columns were washed thor-
oughly with 0.1% TFA to remove salts and buffers. Fi-
nally, the tryptic peptides were eluted with 70%
acetonitrile twice (250 μl each), the two eluted fractions
were combined and concentrated. The serum glycopep-
tide mixture was fractionated by C-18 RP column (4.6
mm diameter × 150 mm length) using an offline ultim-
ate 3000 HPLC (Dionex, Sunnyvale, CA). Mobile phase
A was 2% acetonitrile (ACN) and 0.1% formic acid (FA)
in water, while mobile phase B was 0.1% FA and 90%
ACN in water. Peptides were then eluted from the column
with an 80 min linear gradient from 5 to 80% buffer B at
a flow rate of 200μL/min. A total of 35 fractions were
collected and each fraction was concentrated to 6 μl
under vacuum.
iTRAQ labeling of non-glycosylated peptides
Peptide mixtures were labeled using iTRAQ reagents
following the vendors recommended protocol. Briefly,
each vial of iTRAQ Reagent was allowed to reach room
temperature and spun to bring the solution to the bot-
tom of the tube. 70 μL of ethanol was added to each
iTRAQ reagent vial. Then the solution in each vial was
vortexed to mix and then spun. The contents of one
iTRAQ reagent vial were transferred to one sample tube.
Each tube containing the reaction mixture was vortexed
to mix and then spun. Finally, the reaction mixtures
were incubated at room temperature for 1 hour and
then combined and processed further.
Purification and fractionation of iTRAQ labeled
non-glycosylated peptides by SCX chromatography
The iTRAQ labeled peptides mixture was purified and
fractionated by an off-line HPLC using SCX analytical col-
umn (PolySULFOETHYL A, 200×4.6mm; 5um, 300°A)
(Poly LC Inc.). First, the concentrations of buffer salts and
organics in iTRAQ labeled peptide solution were reduced
by diluting the sample mixture by 10 fold with cation ex-
change buffer-A (10 mM potassium phosphate (KH2PO4)
in 25% acetonitrile at pH 3.0). The sample mixture was
reconstituted with 1 mL cation exchange buffer-load and
vortexed to mix. An aliquot was removed and the pH was
adjusted by adding 1M HCl to bring it down to pH ~3. To
remove the impurities from the peptide mixture, the gra-
dient kept at 5% B in the first 20min and did not collectany fractions. Then the peptides were eluted by buffer–B
(10 mM KH2PO4 in 25% acetonitrile/350 mM potassium
chloride (KCl) at pH 3.0) with the gradient of 0% to 95% B
in 70 min and 95% to 95% B from 70 min to 80 min at a
flow rate of 200μL/min.
Mass spectrometry analysis
A 3000 nano ultimate HPLC (Dionex, Sunnyvale, CA)
was coupled with LTQ mass spectrometer (Thermo
Electron, San Jose, CA) equipped with advanced nanos-
pray source to analyze acetyl (1H3/
2D3) and
18O labeled
peptides. The serum N-deglycosylated peptide fractions
were injected into LC-MS/MS system to identify degly-
cosylated peptides. As a part of on-line sample clean-up
step, the peptides were first concentrated in a C-18 RP
trap column (Dionex) and then separated by using a
75μm ID × 15cm C-18 RP analytical column (Dionex,
Sunnyvale, CA) equilibrated in 4% ACN/0.1% FA at 250
nL/min flow rate. Mobile phase A was 2% ACN and
0.1% FA in water, while mobile phase B was 0.1% FA
and 90% ACN in water. Peptides were separated with a
4% to 50% B in 60 min and 50% to 80% in 90 min and
eluted directly into an LTQ MS. The mass range in MS
mode was 350 Da to 1800 Da and in MS/MS mode it
was set as 100 Da to 2000 Da. N-deglycosylated peptides
were analyzed by normal data dependent mode method
in which the instrument was set to acquire fragment ion
(MS/MS) spectra on the 4 most abundant precursor ions
from each MS scan with a repeat count set of 1 and dur-
ation of 30 sec. Dynamic exclusion was enabled for 180
sec and the collision energy was 33. In a separate experi-
ment, serum non-glycosylated peptide mixtures were
analyzed by an LC-MS/MS experiment (in triplicate)
with a long HPLC linear gradient (4% to 50% B in 120
min and 50% to 80% in 180 min).
The iTRAQ labeled non-glycosylated peptides were ana-
lyzed by data dependent nano LC-MS/MS experiments on
an Velos LTQ-Orbtrap mass spectrometer (Thermo
Fisher) interfaced with a nano ultimate HPLC (Dionex).
The sample was loaded onto a trap column of 100 um ID
X 2 cm (L) packed with 5-μm Magic C18 AQ (200 A, 3
um, Michrom) and washed using 98% H2O, 2% ACN,
0.05% TFA buffer at a flow rate of 10 ul/min for 5 min.
The peptides were then separated by a self-packed 75um
ID X 50 cm (L) fused silica column packed with 3-μm
Magic C18 AQ (200 A, 3 um, Michrom) using a linear
gradient of Buffer B from 4% to 55% in 50 min at a flow
rate of 300 nl/min. The buffer compositions were as fol-
lows: Buffer A was 0.1% formic acid in water, buffer B was
0.1% formic acid, 80% acetonitrile. The analytical column
was coupled to the mass spectrometer via a nano ion
source (Proxeon) with a metal emitter. The peptides were
analyzed in the Orbitrap operated at 60,000 resolution in
full scan (300–2000m/z) followed by 10 Data-Dependent
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and normalized collision energy of 45%. Survey scans were
acquired in profile mode and MS/MS scans were acquired
in centroid mode. Maximum injection times for MS and
MS/MS were set to 500 and 1000ms, respectively. The
precursor isolation width was set at ±1.2 Da and monoiso-
topic precursor selection was enabled to exclude singly
charged ions from MS/MS. The minimum intensity
threshold for MS/MS fragmentation in the Orbitrap
analyzer was 5000 counts and the dynamic exclusion was
set to 60 sec with repeat count as one.
Glycopeptide identification and quantitation
The raw data were converted into DTA files using Bio-
works 3.1 software (Thermo electron, San Jose, CA). All
the ‘DTA’ files were merged and converted into a single
text file using an in-house software program. The pro-
teins were identified by searching this text file of tandem
mass spectrometry data in Swissprot human database
with mascot 2.0 software (MatrixScience, London, U.K).
The database search parameters were: mass type-
monoisotopic precursor and fragment, enzyme–trypsin,
threshold–100, peptide tolerance–1.5 Da, and fragment




2D3), N-deamidation (3 Da), M-oxidation, N-
PNGase18O. The search results, as well as the raw tan-
dem mass spectrometry data were further verified
manually and all glycopeptide sequences were identified
with high confidence based on the presence of NXT/S
motif and a 3 Da mass shift in b or y ions due to the
modification at the N-terminus or K, respectively, by
heavy acetyl (2D3) group.
The isotope ratios of light and heavy forms of glyco-
peptides were calculated manually by Xcalibur software
(Thermo Electron, San Jose, USA) using peak areas
derived from the XIC’s and dividing the area of the
heavy isotope by the area of the light. Similarly, acetyl
(1H3/
2D3) and
18O labeled glycopeptides in the serum
analysis were quantified manually by using Xcalibur soft-
ware program In case of multi-peptide protein identifi-
cation, quantification was performed for at least one






18O+esterification). The ratios of the light and
heavy isotope-labeled peptides were determined by cal-
culating the peak areas found in the corresponding
extracted ion chromatograms (XIC’s) of deglycosylated
peptides obtained with 1 Da mass window. These pep-
tide ratios were also confirmed by the relative intensities
of multiply charged parent peptide peaks in the MS
spectrum. Mean ratios were also calculated for the pep-
tides identified with multiple modifications as light and/
or heavy forms. Final protein ratios were calculated byaveraging the peptide ratios of all modifications. Since
there is only a 3 Da mass difference between differen-
tially labeled deglycosylated peptides and overlapping of
light and heavy isotopic envelops could introduce small
errors in the quantitation, we considered sialylation is
increased in a peptide only if heavy/light ratio of that
peptide is ≥ 2 fold.
Protein identification and quantitation based on the non-
glycosylated peptide analysis
Glycopeptides and their corresponding proteins were
identified by searching the LC-MS/MS raw data using
proteome discoverer software (v 1.3) with Sequest search
algorithm (Thermo). The data generation and database
search parameters were: m.wt range: 375 Da-1500 Da,
threshold: 200 counts, charge state—auto, MSn level—
MS2, activation type—HCD, precursor ion tolerance: 20
ppm, fragment ion tolerance – 0.02 Da, minimum ion
count: 10, in databse - Swissprot human, oxidation of M:
16 Da, N-terminus/K modification by iTRAQ reagents:
144 Da, enzyme - trypsin. The search results were also
verified manually to confidently identify the correct pep-
tide sequence. Quantitation was done by selecting a 4-
plex iTRAQ default method which contains the isobaric
correction parameters for all the iTRAQ labels, however,
only 3 labels (114,115,116) were selected for quantitation
of non-glycosylated peptides. Peptides quantified with ≥
1.5 fold increase and with ≤ 1.5 fold decrease in concen-
tration were considered as up regulated and down regu-
lated, respectively, in the current analysis.
Western blot analysis
Validation of differentially sialylated glycoproteins
For each selected protein, 10 ug of each of the indicated
serum samples were resolved on a 10% Tris-Glycine gel
and the proteins were transferred onto PVDF membrane
using a wet transfer apparatus. Various proteins in the
serum (Haptoglobin, PON1, Zinc Alpha 2 glycoprotein)
were probed with a 1:1000 dilution of commercial anti-
bodies in Odyssey blocking buffer + 0.1% Tween 20
[Sigma, catalog #H8636 (anti-Haptoglobin); Abcam,
catalog #ab24261 (anti-PON1); Abcam, catalog
#ab47116 (anti-zinc alpha 2 glycoprotein)] followed by a
1:5000 dilution of secondary reagents in Odyssey block-
ing buffer + 0.1% Tween 20 [Licor Biosciences, catalog
#926-32210 (anti-mouse IgG IRDye800CW) or catalog
#926-32211 (anti-rabbit IgG IRDye 800CW)]. Blot was
developed using fluorescence detection on the Odyssey
Infrared Imaging System from Licor Biosciences.
Individual patient sample analysis
Western blot analysis was also performed on individual
samples obtained from serous, endometroid and clear
cell carcinoma of stage I and Stage II-IV ovarian cancer
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enrichment and probed with PON1 or haptoglobin anti-
bodies. Pooled stage I and stage II-IV samples were also
subjected to western blot experiments where pooled
healthy female sample used as control. Serum samples
were analyzed individually or pooled (Before) and 100uL
of these were enriched using SNA Lectin as per the
product protocol (Vector Labs AL-1303) (After). Follow-
ing enrichment, approximately 300ug were taken and
treated with PNGase in the presence of a 1× protease in-
hibitor cocktail and 5% NP40 for 2 hours at 37°C. Fol-
lowing treatment with SNA, the protein concentrations
were determined using the BCA Assay. Samples were
loaded on a 10% TrisGlycine gel as follows - for PON1,
5ug of the Before samples and 2.4ug of the After sam-
ples were loaded/well; for Haptoglobin, 1ug of each sam-
ple was loaded/well, and the proteins were transferred
onto PVDF membrane using a wet transfer apparatus.
The membranes were blocked using Odyssey Blocking
Buffer and probed with Haptoglobin (Sigma H8636) and
PON1 (abcam ab24261) antibodies, followed by a corre-
sponding IRDye secondary antibody (Licor Biosciences
#926-32210 or #926-68021). The blot was developed using
the Odyssey Infrared Imaging System (Licor Biosciences).Investigation of O-sialylated glycoprotein contribution
Glycoproteins were enriched from 100uL each of the
pooled serum samples using SNA Lectin as per the
product protocol (Vector Labs AL-1303). Following en-
richment, approximately 300ug of the sample was trea-
ted with PNGase in the presence of a 1× protease
inhibitor cocktail and 5% NP40 for 2 hours at 37°C.
After treatment with SNA and/or PNGase, the protein
concentrations were determined using the BCA Assay.
Ten microgram of the sample was loaded/well on a 10%
TrisGlycine gel and the proteins were transferred onto
PVDF membrane using a wet transfer apparatus. The
membranes were blocked using Odyssey Blocking Buffer
and probed with Haptoglobin (Sigma H8636) antibodies
followed by a corresponding IRDye secondary antibody
(Licor Biosciences #926-32210 or #926-68021). The blot
was developed using the Odyssey Infrared Imaging Sys-
tem (Licor Biosciences).
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